What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy. Pharamphorum outlined the study in an article here.
The study found that the majority (67%) of PTSD patients that participated in three MDMA-assisted therapy sessions had such positive results, that the patients no longer qualified for a PTSD diagnosis.
